Receptor
From Proteopedia
(Difference between revisions)
Line 122: | Line 122: | ||
This is the largest family of receptors and includes the receptors for several hormones and slow transmitters (dopamine, metabotropic glutamate). They are composed of 7 transmembrane alpha helices. The loops connecting the alpha helices form extracellular and intracellular domains. The binding-site for larger peptide ligands is usually located in the extracellular domain whereas the binding site for smaller non-peptide ligands is often located between the seven alpha helices and one extracellular loop. These receptors are coupled to different intracellular effector systems via G proteins | This is the largest family of receptors and includes the receptors for several hormones and slow transmitters (dopamine, metabotropic glutamate). They are composed of 7 transmembrane alpha helices. The loops connecting the alpha helices form extracellular and intracellular domains. The binding-site for larger peptide ligands is usually located in the extracellular domain whereas the binding site for smaller non-peptide ligands is often located between the seven alpha helices and one extracellular loop. These receptors are coupled to different intracellular effector systems via G proteins | ||
*[[G protein-coupled receptor|G protein-coupled receptors]] | *[[G protein-coupled receptor|G protein-coupled receptors]] | ||
- | + | *[[Neurotensin receptor]] | |
- | + | *[[CXC chemokine receptor type 4]] | |
- | + | *[[Mu Opioid Receptor Bound to a Morphinan Antagonist]] | |
- | + | *[[μ Opioid Receptors]] | |
- | + | *[[Mu Opioid Receptor]] | |
- | * | + | *[[Student Project 3 for UMass Chemistry 423 Spring 2015|The '''κ-opioid receptor''' binds opium-type ligands]]. |
- | * | + | *[[Delta opioid receptor|The '''δ-opioid receptor''' binds enkephalins]] |
- | + | *[[Tutorial: The opioid receptor, a molecular switch]] | |
- | + | *[[Orexin and Orexin receptor]] | |
- | + | *[[Belsomra]] and Orexin receptors | |
- | + | *[[Hypocretin and receptors]] | |
- | + | *[[Human Follicle-Stimulating Hormone Complexed with its Receptor]] | |
- | + | *[[GPR40]] | |
- | + | *[[Lysophosphatidic acid receptor]] | |
- | + | *[[User:Harish Srinivas/Sandbox 1|Sphingosine 1-phosphate Receptor]] | |
- | + | *[[Rhodopsin]] | |
- | + | *[[Rhodopsin Structure and Function]] | |
- | + | *[[5-hydroxytryptamine receptor|Serotonin receptors, main page]] | |
- | + | *[[5-hydroxytryptamine receptor 3D structures|3D structures of Serotonin receptors]] | |
- | + | *[[Adrenergic receptor|Adrenergic receptors in general]] | |
- | + | *[[UMass Chem 423 Student Projects 2011-1#Beta-1 Adrenergic GPCR|Beta-1 Adrenergic receptor]] | |
- | + | *Dobutamine: [[UMass Chem 423 Student Projects 2011-1#Beta-1 Adrenergic GPCR|Beta-1 Adrenergic receptor]], [[2y00]], [[2y01]], [[6h7l]] | |
- | + | *Isoprenaline: [[UMass Chem 423 Student Projects 2011-1#Beta-1 Adrenergic GPCR|Beta-1 Adrenergic receptor]], [[2y03]] | |
- | + | *Carmoterol: [[2y02]] | |
- | + | *Salbutamol: [[2y04]] | |
- | * | + | *[[Adrenergic receptor|Adrenergic receptor page]]. |
- | + | *[[Beta-2 Adrenergic Receptor|Article Beta-2 Adrenergic Receptor by Wayne Decatur, David Canner, Dotan Shaniv, Joel L. Sussman, Michal Harel]] | |
- | + | *[[Beta-2 adrenergic receptor|Article Beta-2 adrenergic receptor by Joel L. Sussman, Tala Curry, Michal Harel, Jaime Prilusky]] | |
- | + | *[[Group:SMART:A Physical Model of the beta-Adrenergic Receptor]] | |
- | + | *G<sub>s</sub>: adenylate cyclase activated, cAMP up. For G<sub>s</sub> see [[Beta2 adrenergic receptor-Gs protein complex updated]] | |
- | + | *[[Dopamine receptor|Dopamine receptors 1 page]] | |
- | + | *[[Dopamine Receptors|Dopamine receptors 2 page]] | |
- | + | *[[Histamine H1 receptor]] | |
- | + | *[[3rze]] - human histamine H1 receptor with an antagonist doxepin | |
- | + | *[[Adenosine A2A receptor]] | |
- | + | *[[Caffeine|Effect of Caffeine (Trimethylxanthine) on Human A2A Receptor]] | |
- | + | *[[Muscarinic acetylcholine receptor]] | |
- | + | *[[Glucose-dependent Insulinotropic Polypeptide Receptor]] | |
- | + | *[[Glucagon receptor]] | |
- | + | *[[Glucagon-like peptide 1 receptor]] | |
- | + | *[[Metabotropic glutamate receptor|Metabotropic Glutamate Receptors]] | |
- | + | *[[Ligand Binding N-Terminal of Metabotropic Glutamate Receptors]] | |
- | + | *[[Metabotropic glutamate receptor 5]] | |
- | + | ||
==Kinase-linked, enzyme-linked and related receptors== | ==Kinase-linked, enzyme-linked and related receptors== |
Revision as of 11:53, 14 April 2021
|
References
- ↑ De Rienzo F, Moura Barbosa AJ, Perez MA, Fernandes PA, Ramos MJ, Menziani MC. The extracellular subunit interface of the 5-HT(3) receptors: a computational alanine scanning mutagenesis study. J Biomol Struct Dyn. 2012 Jul;30(3):280-98. Epub 2012 Jun 12. PMID:22694192 doi:10.1080/07391102.2012.680029
- ↑ 2.0 2.1 Barnes, N., Hales, T., Lummis, S., & Peters, J. (2009). The 5-HT3 receptor – the relationship between structure and function. Neuropharmacology, 273-284
- ↑ Perumal, R., & Mahesh, R. (2006). Synthesis and biological evaluation of a novel structural type of serotonin 5-HT3 receptor antagonists. Bioorganic & Medicinal Chemistry Letters, 2769-2772.
- ↑ 4.0 4.1 Hassaine, G., Deluz, C., Grasso, L., Wyss, R., Tol, M., Hovius, R., . . . Nury, H. (2014). X-ray structure of the mouse serotonin 5-HT3 receptor. Nature, 276-281.
- ↑ De Rienzo F, Moura Barbosa AJ, Perez MA, Fernandes PA, Ramos MJ, Menziani MC. The extracellular subunit interface of the 5-HT(3) receptors: a computational alanine scanning mutagenesis study. J Biomol Struct Dyn. 2012 Jul;30(3):280-98. Epub 2012 Jun 12. PMID:22694192 doi:10.1080/07391102.2012.680029
- ↑ Moura Barbosa AJ, De Rienzo F, Ramos MJ, Menziani MC. Computational analysis of ligand recognition sites of homo- and heteropentameric 5-HT3 receptors. Eur J Med Chem. 2010 Nov;45(11):4746-60. Epub 2010 Jul 27. PMID:20724042 doi:10.1016/j.ejmech.2010.07.039
- ↑ Moreira IS, Fernandes PA, Ramos MJ. Computational alanine scanning mutagenesis--an improved methodological approach. J Comput Chem. 2007 Feb;28(3):644-54. PMID:17195156 doi:10.1002/jcc.20566
- ↑ De Rienzo F, Moura Barbosa AJ, Perez MA, Fernandes PA, Ramos MJ, Menziani MC. The extracellular subunit interface of the 5-HT(3) receptors: a computational alanine scanning mutagenesis study. J Biomol Struct Dyn. 2012 Jul;30(3):280-98. Epub 2012 Jun 12. PMID:22694192 doi:10.1080/07391102.2012.680029
- ↑ De Rienzo F, Del Cadia M, Menziani MC. A first step towards the understanding of the 5-HT(3) receptor subunit heterogeneity from a computational point of view. Phys Chem Chem Phys. 2012 Sep 28;14(36):12625-36. Epub 2012 Aug 9. PMID:22880201 doi:10.1039/c2cp41028a
- ↑ Wo ZG, Oswald RE. Unraveling the modular design of glutamate-gated ion channels. Trends Neurosci. 1995 Apr;18(4):161-8. PMID:7539962
- ↑ Turski L, Huth A, Sheardown M, McDonald F, Neuhaus R, Schneider HH, Dirnagl U, Wiegand F, Jacobsen P, Ottow E. ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10960-5. PMID:9724812
- ↑ Walters MR, Kaste M, Lees KR, Diener HC, Hommel M, De Keyser J, Steiner H, Versavel M. The AMPA antagonist ZK 200775 in patients with acute ischaemic stroke: a double-blind, multicentre, placebo-controlled safety and tolerability study. Cerebrovasc Dis. 2005;20(5):304-9. Epub 2005 Aug 30. PMID:16131799 doi:10.1159/000087929
- ↑ Wo ZG, Oswald RE. Unraveling the modular design of glutamate-gated ion channels. Trends Neurosci. 1995 Apr;18(4):161-8. PMID:7539962
- ↑ Wood MW, VanDongen HM, VanDongen AM. Structural conservation of ion conduction pathways in K channels and glutamate receptors. Proc Natl Acad Sci U S A. 1995 May 23;92(11):4882-6. PMID:7761417
- ↑ Doyle DA, Morais Cabral J, Pfuetzner RA, Kuo A, Gulbis JM, Cohen SL, Chait BT, MacKinnon R. The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science. 1998 Apr 3;280(5360):69-77. PMID:9525859
- ↑ Segaliny AI, Tellez-Gabriel M, Heymann MF, Heymann D. Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers. J Bone Oncol. 2015 Jan 23;4(1):1-12. doi: 10.1016/j.jbo.2015.01.001. eCollection , 2015 Mar. PMID:26579483 doi:http://dx.doi.org/10.1016/j.jbo.2015.01.001
- ↑ Li MJ, Greenblatt HM, Dym O, Albeck S, Pais A, Gunanathan C, Milstein D, Degani H, Sussman JL. Structure of estradiol metal chelate and estrogen receptor complex: The basis for designing a new class of selective estrogen receptor modulators. J Med Chem. 2011 Apr 7. PMID:21473635 doi:10.1021/jm200192y